Abstract
Despite considerable advances in our understanding of the molecular and epigenetic underpinnings of the myelodysplastic syndromes (MDS), this diverse group of myeloid neoplasms remains a significant clinical challenge. Considerable barriers to timely development of effective therapy include the diverse molecular landscape encountered in MDS patients, the difficulty in translating specific molecular aberration into a clinically meaningful animal model, as well as challenges in patient recruitment into clinical trials. These speak to the need to discover efficacious novel therapeutic targets which would in turn translate into improved patient outcomes in terms of both survival and quality of life. In this review, we outline recently published data pertaining to therapeutic advances in TGF-β pathway inhibition, STAT3, Hedgehog signaling, and additional therapeutic venues being actively explored in MDS.
Article PDF
Avoid common mistakes on your manuscript.
References
Makishima, H, Yoshizato, T, Yoshida, K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 2017;49; 204–12.
Arber, DA, Orazi, A, Hasserjian, R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127;2391–405.
Song, Y, Rongvaux, A, Taylor, A, et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nat Commun 2019;10;366.
Steensma, DP, Brunner, AM, DeZern, AE, et al. Low clinical trial accrual of patients with myelodysplastic syndromes: causes and potential solutions. Cancer 2018;124;4601–9.
Sekeres, MA, Steensma, DP. Rethinking clinical trial endpoints in myelodysplastic syndromes. Leukemia 2019;33;570–5.
Benton, CB, Khan, M, Sallman, D, et al. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 2018;93;1245–53.
Falconi, G, Fabiani, E, Piciocchi, A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia 2019;33;785–90.
Garcia-Manero, G. Improving prognostic tools for patients with myelodysplastic syndromes, Mayo Clin Proc 2018;93;1340–2.
Lindsley, RC, Saber, W, Mar, BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 2017;376;536–47.
Kennedy, JA, Ebert, BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol 2017;35;968–74.
Lindsley, RC. Uncoding the genetic heterogeneity of myelodys-plastic syndrome. Hematology Am Soc Hematol Educ Program 2017;2017;447–52.
Shiozawa, Y, Malcovati, L, Galli, A, et al. Gene expression and risk of leukemic transformation in myelodysplasia. Blood 2017;130;2642–53.
Yeh, P, Dickinson, M, Ftouni, S, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood 2017;129;1685–90.
Blank, U, Karlsson, S. TGF-beta signaling in the control of hematopoietic stem cells. Blood 2015;125;3542–50.
Muench, DE, Ferchen, K, Velu, CS, et al. SKI controls MDS-associated chronic TGF-beta signaling, aberrant splicing, and stem cell fitness. Blood 2018;132;e24–e34.
Zhao, M, Perry, JM, Marshall, H, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med 2014;20; 1321–6.
Yamazaki, S, Ema, H, Karlsson, G, et al.Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011;147;1146–58.
Zhou, L, McMahon, C, Bhagat, T et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 71;2011;955–63.
Blank, U, Karlsson, S. The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 2011;25; 1379–88.
Chapnick, DA, Warner, L, Bernet, J, Rao, T, Liu, X. Partners in crime: the TGFbeta and MAPK pathways in cancer progression. Cell Biosci 2011;1;42.
Massague, J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012;13;616–30.
Valcarcel, D, Verma, A, Platzbecker, U, et al. Phase 2 Study of monotherapy galunisertib (LY2157299 monohydrate) in very low-, low-, and intermediate-risk patients with myelodysplastic syndromes. Blood 2015;126;1669.
Mies, A, Hermine, O, Platzbecker, U. Activin receptor II lig- and traps and their therapeutic potential in myelodysplastic syndromes with ring sideroblasts. Curr Hematol Malig Rep 2016; 11;416–24.
Komrokji, R, Garcia-Manero, G, Ades, L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol 2018;5;e63–e72.
Suragani, RN, Cadena, SM, Cawley, SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014; 20;408–14.
Attie, KM, Allison, MJ, McClure, T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 2014;89;766–70.
Platzbecker, U, Germing, U, Gotze, KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017;18;1338–47.
Will, B, Zhou, L, Vogler, TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120;2076–86.
Kanna, R, Choudhary, G, Ramachandra, N, Steidl, U, Verma, A, Shastri, A. STAT3 inhibition as a therapeutic strategy for leukemia. Leuk Lymphoma 2018;59;2068–74.
Shastri, A, Choudhary, G, Teixeira, M, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest 2018;128;5479–88.
Wellbrock, J, Latuske, E, Kohler, J, et al. Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res 2015;21;2388–98.
Heidel, FH, Arreba-Tutusaus, P, Armstrong, SA, Fischer, T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia’s genetic diversity. Clin Cancer Res 2015;21;240–8.
Savona, MR, Pollyea, DA, Stock, W, et al. Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. Clin Cancer Res 2018;24;2294–303.
Cortes, JE, Douglas Smith, B, Wang, ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol 93;2018;1301–10.
Cortes, JE, Heidel, FH, Hellmann, A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 2019;33;379–89.
Lau, BW, Huh, K, Madero-Marroquin, R, et al. Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. Oncogene 2019;38;687–98.
Ozawa, Y, Sugi, NH, Nagasu, T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001;37;2275–82.
Assi, R, Kantarjian, HM, Kadia, TM, et al. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2018;124; 2758–65.
Han, T, Goralski, M, Gaskill, N et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 2017;28;356(6336).
Cluzeau, T, Sebert, M, Rahmé, R, et al. APR-246 combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a phase 2 study by the Groupe Francophone Des Myélodysplasies (GFM). Blood 2019;134;677.
Cameron, EE, Bachman, KE, Myohanen, S, Herman, JG, Baylin, SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21;103–7.
Garcia-Manero, G, Montalban-Bravo, G, Berdeja, JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 2017;123;994–1002.
Savona, MR, Odenike, O, Amrein, PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol 2019;6;e194–e203.
Seiler, M, Yoshimi, A, Darman, R, et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat Med 2018;24;497–504.
Steensma, DP, Wermke, M, Klimek, VM, et al. Results of a clinical trial of H3B-8800, a splicing modulator, in patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood 2019;134;673.
Dickinson, M, Cherif, H, Fenaux, P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood 2018;132;2629–38.
Jilg, S, Hauch, RT, Kauschinger, J, et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. Exp Hematol Oncol 2019;8:9.
Foran, JM, DiNardo, CD, Watts, JM, et al. Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study. Blood 2019;134;4254.
Richard-Carpentier, G, DeZern, AE, Takahashi, K, et al. Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated Myelodysplastic Syndromes (MDS). Blood 2019;134;678.
Ramos Perez, JM, Kadia, TM, Montalban-Bravo, G, et al. Liposomal cytarabine and daunorubicin (CPX-351) in combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 134;2019;2642.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Canaani, J. Emerging Therapies for the Myelodysplastic Syndromes. Clin Hematol Int 2, 13–17 (2020). https://doi.org/10.2991/chi.d.191202.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.191202.001